Tumor Traits May Predict Who Responds to Lighter HER2+ Breast Cancer Chemo
Tumor Traits May Predict Who Responds to Lighter HER2+ Breast Cancer Chemo Cure Today
Tumor Traits May Predict Who Responds to Lighter HER2+ Breast Cancer Chemo Cure Today
A randomized phase 2B trial of a novel peptide-based vaccine missed its primary endpoint, as the immunotherapy failed to significantly extend survival compared with placebo in newly diagnosed glioblastoma, according to a press release. However, topline data showed SurVaxM (MimiVax Inc.) may have the potential to delay…
FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer Pharmaceutical Executive
Tennessee Oncology Physician Contributes to Landmark Longevity Research PR Newswire
Putting Patients at the Heart of Cancer Research – EORTC Oncodaily
FDA Approves Tukysa Combination as Maintenance for HER2-Positive Breast Cancer Cure Today
Вакцина от туберкулёза лечит рак мочевого пузыря: неожиданное применение, которое работает ИА Чеченинфо
“A Missed Mutation Can Mean a Missed Treatment”: Study Supports Two Approaches to ESR1 Testing Oncology News Central
Врачи бьют тревогу: В Латвии рак груди ежегодно выявляют более чем у тысячи женщин BB.LV
Врачи бьют тревогу: В Латвии рак груди ежегодно выявляют более чем у тысячи женщин BB.LV
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer Business Wire
Скрытый резерв опухолевых клеток: как ошибка в системе регенерации привела к необратимому финалу Правда.Ру
A research team has developed an anticancer treatment platform that simultaneously targets cancer cells and the surrounding cells that support them while blocking communication between the two.